ImageneBio, Inc.
ImageneBio, Inc. (Nasdaq: IMA) is a clinical-stage biopharmaceutical company developing therapies for immunological, autoimmune and inflammatory diseases. Its lead candidate, IMG-007, is a non-depleting monoclonal antibody that blocks the OX40 receptor’s interaction with OX40 ligand, and is initially being evaluated… From the company’s description.
In fiscal 2025, ImageneBio, Inc. reported revenue of $0.80M, down 77.1% from fiscal 2024, and a net loss of $45.35M. Operations used $47.84M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What ImageneBio, Inc. does
In the company’s own words
ImageneBio, Inc. (Nasdaq: IMA) is a clinical-stage biopharmaceutical company developing therapies for immunological, autoimmune and inflammatory diseases. Its lead candidate, IMG-007, is a non-depleting monoclonal antibody that blocks the OX40 receptor’s interaction with OX40 ligand, and is initially being evaluated for moderate-to-severe atopic dermatitis. The company is conducting a Phase 2b dose-finding study in adults with atopic dermatitis; earlier clinical studies also evaluated IMG-007 in alopecia areata. The company is exploring potential development in additional conditions, including asthma, rheumatoid arthritis and hidradenitis suppurativa. ImageneBio operates as a single biopharmaceutical business focused on research and clinical development, rather than through reportable operating segments. In July 2025, Ikena Oncology merged with privately held Inmagene Biopharmaceuticals and changed its name to ImageneBio, with the combined company advancing IMG-007. For the fiscal year ended December 31, 2025, the company reported no product revenue. Its website is www.imagenebio.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1835579
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns ImageneBio, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · ImageneBio, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do ImageneBio, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of ImageneBio, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in ImageneBio, Inc.'s last four quarterly filings that the numbers alone won't show?”